Novan Therapeutics, a clinical stage biotech company focused on advancing nitric oxide therapies, will present antiviral data from a preclinical animal study at the 2014 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), taking place September 5-9, 2014, in Washington, DC.
Kimberly Coggan, PhD, Molecular Microbiologist, Novan Therapeutics, will present “Antiviral Efficacy of Nitric Oxide-Releasing Drug Candidates In Vivo Utilizing the Cottontail Rabbit Papillomavirus Model” (Presentation Number V-1822a).
Novan Therapeutics is a privately-held, clinical stage biotech company focused on advancing nitric oxide therapies. Nitric oxide, one of the most studied molecules in human physiology, has been shown to exhibit antimicrobial activity and to promote vasodilation, regulate inflammation, stimulate tissue repair, and eradicate cancer cells.